Berner A, Nesland J M, Waehre H, Silde J, Fosså S D
Department of Pathology, Norwegian Radium Hospital, Oslo.
Br J Cancer. 1993 Aug;68(2):380-4. doi: 10.1038/bjc.1993.344.
Pre- and post-treatment specimens from 47 patients with hormone resistant prostatic carcinoma were compared with each other regarding histological grade and immunoreactivity for p53 protein, neuron specific enolase and c-erbB-2 protein. Significantly more specimens expressed a high malignancy grade when the tumour had become hormone resistant than at the time of initial diagnosis (Gleason P: < 0.0001, WHO P:0.0003). p53 protein immunoreactivity increased significantly with disease progression (P:0.006), while tissue PSA immunoreactivity was reduced in post-treatment specimens (P:0.011). p53 protein expression did not correlate with histological grade or PSA expression and seems to be an independent parameter which participates late in the neoplastic transformation. Thirty-two percent of the tumours were neuron specific enolase positive, but this parameter did not correlate with development of hormone resistance. c-erbB-2 protein reactivity was not recognised.
对47例激素抵抗性前列腺癌患者治疗前和治疗后的标本进行了组织学分级以及p53蛋白、神经元特异性烯醇化酶和c-erbB-2蛋白免疫反应性的比较。与初始诊断时相比,肿瘤出现激素抵抗时,有更多标本表现为高恶性分级(Gleason分级:P < 0.0001,世界卫生组织分级:P = 0.0003)。p53蛋白免疫反应性随疾病进展显著增加(P = 0.006),而治疗后标本中的组织前列腺特异性抗原(PSA)免疫反应性降低(P = 0.011)。p53蛋白表达与组织学分级或PSA表达无关,似乎是一个在肿瘤转化后期起作用的独立参数。32%的肿瘤神经元特异性烯醇化酶呈阳性,但该参数与激素抵抗的发生无关。未检测到c-erbB-2蛋白反应性。